Dolthera

Dolthera is a biotechnology company focused on developing a new class of peptide-based drugs for the treatment of chronic pain and other central nervous system disorders. Spun out from the University of Copenhagen, the company utilizes a proprietary platform to design high-affinity bivalent peptides that target protein-protein interactions. Their primary focus is on the scaffolding protein PSD-95, which plays a crucial role in the signaling pathways associated with pathological pain. By specifically inhibiting these interactions, Dolthera aims to provide potent analgesia without the side effects and addiction potential of opioids. The company is currently advancing its lead candidates through pre-clinical development with support from the BioInnovation Institute.